| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000047833 |
| Receipt No. | R000054530 |
| Scientific Title | A retrospective study investigating the effects of lifestyle-related changes on glycemic changes in patients with type 2 diabetes before and after the epidemic of new coronavirus infection |
| Date of disclosure of the study information | 2022/05/23 |
| Last modified on | 2022/05/23 (Ver. 1) |
| Basic information | ||
| Public title | A retrospective study investigating the effects of the epidemic of new coronavirus infection on lifestyle-related changes in patients with type 2 diabetes | |
| Acronym | A retrospective study investigating the effects of the epidemic of new coronavirus infection on lifestyle-related changes in patients with type 2 diabetes | |
| Scientific Title | A retrospective study investigating the effects of lifestyle-related changes on glycemic changes in patients with type 2 diabetes before and after the epidemic of new coronavirus infection | |
| Scientific Title:Acronym | A retrospective study investigating the effects of lifestyle-related changes on glycemic changes in patients with type 2 diabetes before and after the epidemic of new coronavirus infection | |
| Region |
|
|
| Condition | ||
| Condition | Type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We will evaluate whether there is a difference in HbA1c before and after the epidemic of COVID-19 in type 2 diabetic patients. |
| Basic objectives2 | Others |
| Basic objectives -Others | We will also evaluate changes in lifestyle habits, including exercise habits. |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes in HbA1c before and after the epidemic of COVID-19 |
| Key secondary outcomes | |
| Base | |
| Study type | Others,meta-analysis etc |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Target patients who meet all of the following criteria.
1) Patients with type 2 diabetes who continue to visit our hospital 2) Patients whose necessary data collection items (described later) are all recorded on the electronic medical record |
|||
| Key exclusion criteria | Patients who cannot collect necessary data items in the medical record | |||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kagawa University Hospital | ||||||
| Division name | endocrinology metabolism | ||||||
| Zip code | 761-0793 | ||||||
| Address | 1750-1,Miki-cho, Kita-gun | ||||||
| TEL | 0878912230 | ||||||
| fukunaga.kensaku@kagawa-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kagawa University Hospital | ||||||
| Division name | endocrinology metabolism | ||||||
| Zip code | 761-0793 | ||||||
| Address | 1750-1,Miki-cho, Kita-gun | ||||||
| TEL | 0878912230 | ||||||
| Homepage URL | |||||||
| fukunaga.kensaku@kagawa-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kagawa University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kagawa University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Ethics Committee, faculty of medicine, kagawa university |
| Address | 1750-1,Miki-cho, Kita-gun |
| Tel | 0878912230 |
| fukunaga.kensaku@kagawa-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://www.anncaserep.com/open-access/impact-of-covid19-pandemic-on-glycemic-control-eating-behavio |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.anncaserep.com/open-access/impact-of-covid19-pandemic-on-glycemic-control-eating-behavio | ||||||
| Number of participants that the trial has enrolled | 200 | ||||||
| Results | Two hundred participants completed the survey. During the COVID-19 pandemic, the average HbA1c values significantly deteriorated (7.72%) than those pre-pandemics (7.57%), with an increase of 1.98 percent (p=0.002, r= -0.157). Additionally, the scores for All Physical Activities (all PA) decreased and total eating behaviors improved. There was no significant relationship was found between the HbA1 values, physical activities, and eating behaviors during the pandemic. | ||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | T2D patients | ||||||
| Participant flow | Study involved both retrospective and cross-sectional data analyses. The glycated Hemoglobin (HbA1c) values in patients with type 2 diabetes before the pandemic in 2019 and during pandemic in 2020 were evaluated. A self-administered questionnaire survey was used to measure physical activity and eating behaviors. Patients with type 2 diabetes who had HbA1c values > 7% at any month during 2020 were included. Data collection was performed at the medical outpatient clinic of Kagawa University Hospital. | ||||||
| Adverse events | None | ||||||
| Outcome measures | Changes in HbA1c before and after the epidemic of COVID-19 | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Outbreak of COVID-19 infection among type 2 diabetic patients who are visiting our hospital and who visited our hospital between January 1, 2019 and December 31, 2020. Evaluate whether there is a difference in HbA1c before and after. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054530 |